Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERENA-1: AZD9833 Alone or in Combination in ER-positive, HER2-negative Advanced Breast Cancer
NCT03616587Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2018
- Primary completion
- Sep 2024
- Countries
- 3
01
Overview
Phase 1, open-label trial of camizestrant in breast cancer (14 arms), sponsored by AstraZeneca. Primary endpoints: Dose-Limiting Toxicity at 28 days and Treatment-Related Adverse Events at 1 year. Started Oct 2018; status: active, not recruiting.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03616587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03616587.